Recent News

Time-Limited Venetoclax-Based Combination Therapies for CLL

In Memoriam: Remembering Hematologist Steve E. Coutre, MD

Updated Phase I/II BRUIN Study of Next-Generation BTK Inhibitor Pirtobrutinib in CLL

SEQUOIA Update on Zanubrutinib Versus Bendamustine Plus Rituximab in CLL

Preclinical Findings With Novel CDK9 Inhibitor in CLL

ASH 2021: Update From ASCEND Trial of Acalabrutinib Monotherapy for Resistant CLL

ASH 2021: Updated Phase III FLAIR Results of Ibrutinib Plus Rituximab in Previously Untreated CLL

ASH 2021: Early Results With Zanubrutinib Plus Venetoclax in High-Risk CLL

ASH 2021: Combination Umbralisib and Ublituximab With Ibrutinib in CLL

Immunodeficiency and CLL Associated With IKZF3 Mutation: Focus on One Family

All in the Family: Shared Immunogenetic Characteristics in Familial CLL

Predicting Richter Transformation in Patients With Advanced-Stage CLL

Combination Obinutuzumab Treatment and MRD Kinetics in CLL: Insights From CLL14 Study

Ibrutinib Discontinuation and Risk of Disease Progression: Two Case Studies

Orphan Drug Designation Given to Bispecific Antibody CLL Treatment

Venetoclax and Quality of Life of Patients With Relapsed or Refractory CLL

Mechanistic Insight on Antiapoptotic Multidrug-Resistant Phenotype of CLL

CLL and COVID-19: Clinical and Immunologic Responses Under Study in Sweden

Ibrutinib-Treated Patients With CLL: Clarifying the Risk of Cardiovascular Events

Is Ibrutinib of Benefit for High-Risk, Treatment-Naive Patients With CLL?

What to Consider When Selecting Targeted Agents for CLL

Minimal Residual Disease Testing in CLL: Is It Ready for Prime Time?

Antibody Response in Patients With CLL Following COVID-19 Vaccination

CLL–International Prognostic Index in Predicting Cause of Death in Newly Diagnosed CLL

Predicting Response to COVID-19 Vaccine in Patients With CLL

Emerging Targeted Therapies Under Study in CLL

SOHO 2021: How Does Acalabrutinib Measure Up Against Ibrutinib in CLL?

SOHO 2021: Early-Phase Results With Novel BTK Inhibitor in CLL

SOHO 2021: Understanding Clinical Outcomes in Patients With CLL Older Than 80

SOHO 2021: Case-Based Look at First-Line Therapy for Younger Patients With CLL

SOHO 2021: Can the Natural History of Immune Dysfunction and Infections in CLL Be Altered?

COVID-19 in Patients With CLL: Is Neutropenia a Risk Factor?

Predicting Survival in Patients With CLL: Focus on TP53 Mutations

Statin Use in Patients With CLL: Impact on Survival Outcomes

Can the NOTCH Network Be Used to Refine Risk Stratification in CLL?

Karyotypic Complexity and Evolution May Impact Survival of Ibrutinib-Treated Patients With CLL

Managing CLL During the COVID-19 Pandemic: An Italian Report

Incidence of Neutropenia With Venetoclax and Obinutuzumab in CLL

How Does Acalabrutinib Measure Up Against Ibrutinib in CLL in Phase III Trial?

Case Study: Autoimmune Hemolytic Anemia in Male Patient With CLL

Ibrutinib Plus Venetoclax in CLL: Oral Nonchemotherapy Regimen Under Study

Cohort Study of CLL and Leukemia Cutis From the French Innovative Leukemia Organization